GLPBio

STC-15

Catalog No.: GC73680Purity:>98.00%
COASDSData Sheet
STC-15 es un inhibide la ARN metltransferasa METTL3 activo por vía oral con la actividad de activar la inmunidad antitumoral y remodela el microambiente tumoral.

Los productos son exclusivamente para uso en investigación. No aptos para uso humano. No vendemos a pacientes.

STC-15
Cas No.: 2648257-56-9
10mM (in 1mL DMSO)In Stock
$73.00
1
1mgIn Stock
$40.00
1
5mgIn Stock
$80.00
1
10mgIn Stock
$120.00
1
25mgIn Stock
$220.00
1
50mgIn Stock
$352.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Citas (Citations)

Actualmente no hay citas disponibles para este producto. A continuación se muestran publicaciones seleccionadas que citan productos GlpBio.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Descripción (Description)

STC-15 is a potent, selective and orally active inhibitor of RNA methyltransferase METTL3, with an IC50 value of 6.1nM [1]. STC-15 can activate the innate immune pathway and modify the tumor microenvironment (TME), transforming the TME from an immunosuppressive, tumor-promoting state to an immunostimulatory, anti-tumor state[2]. STC-15 has been widely used in inhibiting tumor progression in cell and animal models, as well as in the development of novel combined therapies[3].

In vitro, STC-15 treatment combined with HJP-178 for 7 days significantly inhibited the proliferation of SKOV-3 cells, with IC50 values of 1.194μM[4]. STC-15 treatment (0.5µM) for 48h induced the expression of endogenous IFN signaling in the Caov3 ovarian cell line[5].

In vivo, STC-15 treatment via intraperitoneal injection at a dose of 30mg/kg/day for 2 days significantly reduced the cellular level of m6A in peripheral blood mononuclear cells (PBMC) of SD rats[6].

References:
[1] Tang H, Zhang R, Zhang A. Small-molecule inhibitors targeting RNA m6A modifiers for cancer therapeutics: latest advances and future perspectives[J]. Journal of Medicinal Chemistry, 2025, 68(17): 18114-18142.
[2] Ofir-Rosenfeld Y, Vasiliauskaitė L, Obacz J, et al. Abstract C077: STC-15, a small molecule inhibitor of the RNA methyltransferase METTL3, activates anti-tumor immunity and reshapes the tumor microenvironment[J]. Molecular Cancer Therapeutics, 2023, 22(12_Supplement): C077-C077.
[3] Vasiliauskaite L, Ofir-Rosenfeld Y, Albertella M, et al. Abstract A18: STC-15, a novel METTL3 inhibitor, and its combination with Venetoclax confer anti-tumour activity in AML models[J]. Blood Cancer Discovery, 2023, 4(3_Supplement): A18-A18.
[4] Ou Y J, Liu B J, Xuan Y F, et al. The combination of BET and METTL3 inhibitors elicits synergistic antitumor effects in ovarian cancer cells via reducing SP1 and BCL-2 expression[J]. Life Sciences, 2025, 368: 123505.
[5] Ofir-Rosenfeld Y, Vasiliauskaitė L, Obacz J, et al. STC-15, a small molecule inhibitor of the RNA methyltransferase METTL3, activates anti-tumor immunity and reshapes the tumor microenvironment[C]//MOLECULAR CANCER THERAPEUTICS. 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA: AMER ASSOC CANCER RESEARCH, 2023, 22(12).
[6] Dutheuil G, Oukoloff K, Korac J, et al. Discovery, optimization, and preclinical pharmacology of EP652, a METTL3 inhibitor with efficacy in liquid and solid tumor models[J]. Journal of Medicinal Chemistry, 2025, 68(3): 2981-3003.

Protocolo (Protocol)

Cell experiment [1]:

Cell lines

SKOV-3 cells

Preparation Method

SKOV-3 cells were cultured in DMEM medium containing 10% fetal bovine serum (FBS) at 37℃ in the presence of 5% CO2. SKOV-3 (1500 cells/well) were seeded into six-well plates for the formation of colonies. Cells were cultured overnight and treated with different concentrations of STC-15 (1.562, 3.125, 6.25, 12.5, 25, and 50μM) for another 7 days. After being fixed, the cell colonies were stained with sulforhodamine B (SRB) and the numbers of colonies per well were counted.

Reaction Conditions

1.562, 3.125, 6.25, 12.5, 25, and 50μM; 7 days

Applications

STC-15 treatment suppressed the cell proliferation of SKOV-3 cells in a dose-dependent manner.
Animal experiment [2]:

Animal models

Male SD rats

Preparation Method

Male SD rats were group-housed in cages with bedding material, and were housed in a room with controlled humidity (50±10%) and temperature (25±3°C) under a 12/12h light/dark cycle. All mice were adaptively fed for one week. The rats were intraperitoneally injected with 30mg/kg/day dose of STC-15 or 3mg/kg/day dose of EP652 for two days. PBMC samples were collected from the rats for analysis.

Dosage form

30mg/kg/day for 2 days; i.p.

Applications

STC-15 treatment significantly reduced the cellular level of m6A in PBMCs of SD rats.

References:
[1] Ou Y J, Liu B J, Xuan Y F, et al. The combination of BET and METTL3 inhibitors elicits synergistic antitumor effects in ovarian cancer cells via reducing SP1 and BCL-2 expression[J]. Life Sciences, 2025, 368: 123505.
[2] Dutheuil G, Oukoloff K, Korac J, et al. Discovery, optimization, and preclinical pharmacology of EP652, a METTL3 inhibitor with efficacy in liquid and solid tumor models[J]. Journal of Medicinal Chemistry, 2025, 68(3): 2981-3003.

Documentos del producto (Product Documents)

Purity:>98.00%Appearance:A solid
COASDSData Sheet

Propiedades químicas (Chemical Properties)

N.º CAS
2648257-56-9
Fórmula molecular
C24H25N5O2
Peso molecular
415.49
Solubilidad
DMSO : 116.67 mg/mL (280.80 mM; Need ultrasonic)
Almacenamiento
-20°C
Consejos generales
Seleccione un disolvente adecuado según los datos de solubilidad del producto. Una vez preparada, divida la solución madre en alícuotas para evitar ciclos repetidos de congelación y descongelación.
Utilice las soluciones madre en un plazo de 6 meses si se conservan a -80°C, o de 1 mes si se conservan a -20°C.
Para mejorar la solubilidad, caliente el tubo a 37°C y soníquelo durante un periodo adecuado.
Condiciones de envío
Las muestras de evaluación se envían con acumuladores de frío. Los demás tamaños se envían a temperatura ambiente o, previa solicitud, con acumuladores de frío.

Calculadoras (Calculators)Molaridad / Dilución / Peso molecular / Conversión de unidades / Formulación in vivo / Solubilidad

g/mol

Reviews

Review for STC-15

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%